Skip to main content
. 2024 Aug 15;8:100122. doi: 10.1016/j.sleepx.2024.100122

Table 3.

Summary of end-of-study questionnaire.

Question, n (%)
Switch Participants
N = 68
Since you started taking ON-SXB, how is your narcolepsy?
 Much better 23 (33.8)
 Somewhat better 20 (29.4)
 About the same 24 (35.3)
 Worse 1 (1.5)
Compared to other treatments you've taken for narcolepsy, how satisfied are you with ON-SXB?
 Very satisfied 54 (79.4)
 Somewhat satisfied 11 (16.2)
 Neither satisfied nor dissatisfied 2 (2.9)
 Definitely not satisfied 1 (1.5)
If your friend or a family member had narcolepsy, would you recommend ON-SXB to them?
 Yes, definitely 63 (92.6)
 Not sure/no opinion 5 (7.4)
Since starting treatment with ON-SXB, would you say any of the statements below are true? If you agree, check “Yes.” If you don't agree, check “No.”
 I am better able to get through the day without falling asleep
 Yes 43 (63.2)
 No 14 (20.6)
 Not sure 11 (16.2)
 I am better able to sleep through the night
 Yes 62 (91.2)
 No 4 (5.9)
 Not sure 2 (2.9)
 I am getting more done at work/school
 Yes 40 (58.8)
 No 11 (16.2)
 Not sure 17 (25.0)
 I am better able to socialize with friends or family
 Yes 41 (60.3)
 No 11 (16.2)
 Not sure 16 (23.5)
Since switching from IR oxybate, please tell us if you agree with the following statement. If you agree, check “Yes.” If you don't agree, check “No.”
 I am better able to follow the recommended medication schedule
 Yes 62 (91.2)
 No 3 (4.4)
 Not sure 3 (4.4)
Are there any daily activities that you previously could not do, or now can do better, since you started ON-SXB?
 If yes, please briefly describe 25 (36.8)
 No 27 (39.7)
 Not sure 16 (23.5)

ON-SXB is LUMRYZ™ (Avadel Pharmaceuticals, Chesterfield, MO). IR oxybate includes Xyrem® (Jazz Pharmaceuticals, Inc., Palo Alto, CA) or Xywav® (Jazz Pharmaceuticals, Inc., Palo Alto, CA). IR, immediate-release.